Graphic: corner
spacer
Graphic: corner
spacer spacer
nav left edge
nav right edge
spacer

Updated News Release to our U.S. customers 5/1/09:

Second lawsuit filed to protect patents 4/17/09:

OptiGen continues to protect its intellectual property from infringement and has filed a second lawsuit against Dobbins et al., including Shelterwood Laboratories and Texas A&M University System. This complaint, filed April 17, 2009, seeks to protect OptiGen from other parties' unlawful use of DNA tests for CLAD, CSNB (Retinal Dystrophy) and FN (Autosomal Recessive Nephropathy).  This technology is exclusively licensed to OptiGen for use in the USA and OptiGen intends to enforce its rights to the fullest extent.

Notice of lawsuit 1/14/09:

You may have recently received offers from foreign corporation(s) to have your dog tested for PRCD outside of the U.S. to avoid patent protection here.  However, offering to sell and selling an invention patented in the U.S. are activities that have been found to be violations of U.S. patent law.

OptiGen, LLC has filed a lawsuit arising out of the infringement of two patents related to the genetic testing of dogs for Progressive Rod-Cone Degeneration.  On January 5, 2009, OptiGen filed a complaint charging Richard Dobbins of Georgia and two of his companies, International Genetics, Inc. (InGen) and PinPoint DNA Technologies, Inc. with the willful infringement of the patents.  Genetic Fulfillment USA, LLC is also a defendant.

PinPoint and Dobbins infringed the patents by using OptiGen's patented methods to test for PRCD.  When the infringement was detected by OptiGen, PinPoint discontinued the PRCD test.  PinPoint's assets were then transferred to InGen, a company based in Freeport, The Bahamas, and InGen has been offering the test through its offshore operation.  The case, which is in preliminary stages, is pending in federal court in Syracuse, New York.

OptiGen was one of the first companies to offer DNA tests for dog diseases, and it was founded with the initial specific mission of testing PRA in purebred dogs.  The research that resulted in the identification of many PRA mutations, including PRCD, as well as other important eye diseases of dogs, e.g. CEA and OSD, is based on decades of research by scientists associated with OptiGen.  OptiGen is committed to enforcing its intellectual property rights.  We continue to be committed to providing dog owners and breeders with the best quality, service and ongoing research possible in DNA testing for canine diseases, particularly those involving the eye.  We appreciate our valued clients and look forward to serving your needs to the best of our ability for years to come.


spacer
Graphic: footer bar left
OptiGen®, LLC · Cornell Business & Technology Park · 767 Warren Road, Suite 300 · Ithaca, New York 14850
Tel: 607 257 0301 · Fax: 607 257 0353 · email: genetest@optigen.com or optigen@clarityconnect.com
Graphic: footer bar right
spacer spacer
spacer
spacer
spacer